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Abstract
Background—In 2009, the quadrivalent Human Papillomavirus (HPV) vaccine was licensed by 
the Food and Drug Administration (FDA) for use in males 9 through 26 years. In 2009, the 
Advisory Committee on Immunization Practices (ACIP) provided a permissive recommendation 
allowing the administration of HPV vaccine to males 9 through 26 years.
Purpose—To assess HPV vaccination coverage, evaluate awareness of HPV and HPV vaccine, 
and identify factors independently associated with awareness of HPV and HPV vaccine among 
men 18-26 years.
Methods—We analyzed data from the 2010 National Health Interview Survey (NHIS), to 
evaluate initiation of HPV vaccination, assess awareness of HPV and the HPV vaccine, and 
identify factors associated with awareness of HPV and the HPV vaccine among men 18–26 years.
Results—In 2010, HPV vaccination initiation among men 18-26 years was 1.1%. Among the 
1,741 men 18-26 years interviewed, nearly half had heard of HPV (51.8%). Overall, about one 
third of men 18-26 years had heard of the HPV vaccine (34.8%). Factors independently associated 
with a higher likelihood of awareness of both HPV and HPV vaccine among men 18-26 years 
included non-Hispanic white race/ethnicity, higher education, birth in the United States, a greater 
number of physician contacts, private health insurance, receipt of other vaccines, and reporting 
risk behaviors related to sexually transmitted diseases, including HIV.
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Conclusions—HPV vaccination initiation among men 18-26 years in 2010 was low. HPV and 
HPV vaccine awareness were also low and communication messages directed to men are needed. 
Since ACIP published a recommendation for routine use of HPV4 among males in December 
2011, continued monitoring of HPV vaccination uptake among men 18-26 years is useful for 
evaluating the vaccination campaigns and for planning and implementing strategies for increasing 
vaccination coverage.
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Introduction
Human papillomavirus (HPV) is the most common sexually transmitted infection in the 
United States; an estimated 6.2 million persons 14-44 years are newly infected every year 
1, 2
. Of these new infections, 74% occur among persons 15-24 years1. More than 50% of 
sexually active men and women will acquire HPV infection in their lifetime3. HPV-related 
cancers in males include some anal, penile, and oropharyngeal cancers caused primarily by 
HPV type 16 4-8; approximately 7,000 HPV type 16- and 18-related cancers occur among 
males each year4. Studies indicate that incidence of oropharyngeal and anal cancers in men 
are increasing4, 7, 8; an evaluation of data from 1973–2007 found increases of 1% per year 
for oropharyngeal cancers and 3% per year for anal cancers8. Additionally, approximately 
250,000 cases of genital warts occur each year in the United States among sexually active 
males 9, 10.
In June 2006, HPV vaccine (HPV4; Gardasil, Merck & Co. Inc.), directed against HPV 
types 6, 11, 16, and 18, was licensed by the Food and Drug Administration (FDA) for use in 
females1. In October 2009, the quadrivalent HPV vaccine was licensed by the Food and 
Drug Administration (FDA) for use in males 9 through 26 years for prevention of genital 
warts caused by HPV. Also in October 2009, the Advisory Committee on Immunization 
Practices (ACIP) voted and provided guidance that the HPV4 vaccine may be given to males 
9 through 26 years noting that men who have sex with men (MSM) are particularly at risk 
for conditions associated with HPV infection, and this guidance was officially published in 
May 201011, 12. The committee did not recommend routine use for males at that time12. In 
October, 2011, ACIP recommended routine use of HPV4 among males 11 or 12 years and 
recommended HPV4 for males through 21 years who have not been vaccinated previously or 
who have not completed the 3-dose series. Men 22 through 26 years may also be vaccinated. 
HPV vaccination is recommended through 26 years for men who have sex with men and 
men who are immunocompromised (such as those with human immunodeficiency (HIV) 
infection) who had not been previously vaccinated4. Optimal use of vaccination strategies 
could potentially reduce burden of HPV-related disease among males11, 12. Monitoring HPV 
vaccine initiation after vaccine licensure is important for evaluating the vaccination 
campaigns and for planning and implementing strategies for increasing vaccination 
coverage.
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Limited studies evaluated and discussed HPV uptake and awareness of HPV and HPV 
vaccine among male adolescents13, 14. Little is known regarding national level of HPV 
vaccination uptake and awareness of HPV and HPV vaccine among younger US male adult. 
The purpose of this study is to address and examine the following questions using the 2010 
National Health Interview Survey (NHIS): (1) What is HPV vaccination initiation for men 
18–26 years within 3 to 14 months after HPV4 was first licensed for males? (2) What are 
awareness levels of HPV and HPV vaccine among men 18-26 years? (3) What factors are 
independently associated with awareness of HPV and HPV vaccine among men 18-26 
years? This study provides an opportunity to establish baseline indicators from which the 
impact of universal/routine recommendation can be determined. This study also identifies 
opportunities for future intervention focused on addressing low levels of awareness and HPV 
vaccination among males.
Methods
The NHIS is an annual household survey conducted by the National Center for Health 
Statistics of the Centers for Disease Control and Prevention 15. The NHIS sample is selected 
through the use of complex sampling design. Face to face interviews were conducted. In the 
sample adult core, one adult per sampled family was randomly selected and asked to 
complete the sample adult questionnaire15. In 2010, the final response rate for the sample 
adult core was 60.8%15.
To determine awareness of HPV respondents were asked: “Have you ever heard of HPV? 
HPV stands for human papillomavirus?” To determine awareness of HPV vaccine 
respondents were asked: “Have you ever heard of HPV vaccines or shots?” Finally, to 
determine HPV vaccine uptake, respondents were asked: “Have you ever received an HPV 
shot or vaccine?” Those who answered “yes” were asked: “How many HPV shots did you 
receive?”
SUDAAN statistical software (Research Triangle Institute, Research Triangle Park, NC) was 
used to calculate point estimates and 95% confidence intervals (CIs) for vaccine uptake and 
awareness of HPV and HPV vaccine 16. All analyses were weighted to reflect the U.S. non-
institutionalized, civilian population. Bi-variable analysis was conducted and T-tests were 
used to test for difference in vaccine uptake and awareness of HPV and HPV vaccine for 
each variable. Due to the low levels of HPV vaccine initiation, we were unable to conduct a 
multivariable analysis to further assess factors independently associated with HPV vaccine 
initiation. Multivariable logistic regression model was conducted to identify factors 
independently associated with awareness of HPV and the HPV vaccine using adjusted 
prevalence ratio among men 18-26 years.
Results
The 2010 NHIS surveyed 1,741 men 18-26 years. Men 18-26 years were mostly non-
Hispanic white (60.7%), not married status (86.4%), had private health insurance (54.2%), 
and employed (64.1%). Most of men 18-26 years lived at or above the federal poverty line 
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(76.2%), were born in the United States (86.3%), not hospitalized within past year (95.9%), 
and had a regular physician (64.3%) (Table 1).
HPV vaccine initiation (≥1 dose)
HPV vaccine initiation (≥1 dose) is shown in Table 2. Overall, 1.1% (N=1741; 95% 
CI=0.6%-2.2%) of men 18-26 years reported receiving ≥1 dose of HPV vaccine. 
Approximately 0.1% (95% CI=0.0%-0.5%) of men 18-26 years reported receiving 3 doses 
of vaccine (series completion) (Data not shown).
HPV vaccine initiation was significantly higher among those living below the poverty level 
and those with awareness of HPV and HPV vaccine (p<0.05). Due to the low levels of HPV 
vaccine initiation, we were unable to conduct a multivariable analysis to further assess 
factors independently associated with HPV vaccine initiation.
Awareness of HPV and the HPV vaccine
Overall, 51.8% men 18-26 years had ever heard of HPV, and 34.8% men 18-26 years had 
ever heard of HPV vaccine (Table 3).
In bivariable analyses, among men 18-26 years, the following characteristics were 
significantly associated with ever having heard of HPV and the HPV vaccine: non-Hispanic 
white race, higher educational level, higher income, birth in the United States, increasing 
number of physician contacts, private insurance, past receipt of other recommended 
vaccinations, and reported STD/HIV related high risk behaviors (Table 3).
Additionally, of those interviews conducted during January through May 2010, about 54% 
had ever heard of HPV, and 35% had ever heard of HPV vaccine among men 18-26 years. 
Of those interviews conducted during June through December 2010 (approximately one year 
after vaccine licensure), about 50% had ever heard of HPV, and 34% had ever heard of HPV 
vaccine among men 18-26 years. Awareness of HPV and HPV vaccine were not statistically 
significant between those who were interviewed during January through May 2010 and 
those who were interviewed during June through December 2010 (Table 3).
In multivariable analysis, among men 18-26 years, HPV awareness was lower among 
Hispanics and Asians compared to non-Hispanic whites (Adjusted Prevalence Ratios 0.7, 
0.6, respectively, P-values<0.05). HPV awareness was significantly lower among non-
Hispanic blacks compared with non-Hispanic whites in bivariate analysis (P-value<0.05) but 
the result did not hold after controlling other factors. Awareness was higher among men with 
some college education and education beyond college compared to men with less than high 
school education (Adjusted Prevalence Ratios 1.6, 1.6, respectively, P-values<0.05) (Table 
3). Among men 18-26 years, awareness of HPV vaccine was lower among Hispanic and 
Asian men compared to non-Hispanic white men (Adjusted Prevalence Ratios 0.7, 0.8, 
respectively, P-values<0.05). Awareness was higher among men with some college 
education, and with education beyond college compared to men with less than high school 
education (Adjusted Prevalence Ratios 1.4, 1.6, respectively, P-values<0.05) (Table 3). Other 
characteristics independently associated with a higher likelihood of awareness of both HPV 
and HPV vaccine among men 18-26 years included birth in the United States, a greater 
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number of physician contacts, private health insurance, receipt of other vaccines, and 
reported of STD/HIV related high risk behaviors (Table 3).
Discussion
Our study presents an important source of baseline data when monitoring HPV vaccination 
initiation and HPV awareness among males. The timing of this analysis post-licensure for 
HPV vaccine in males is critical given that the ACIP has issued a routine recommendation 
subsequently4. In this national assessment of interviews conducted about 3 to 14 months 
after the quadrivalent HPV vaccine was first licensed in males and after ACIP provided 
guidance on the use of the vaccine in males, awareness of HPV and HPV vaccine in males 
18-26 years was 52%, and 35%, respectively. Only 1.1% of men 18–26 years had initiated 
HPV vaccination. The result from our study is not surprising because although the vaccine 
was licensed, ACIP only recommended that the HPV vaccine may be used in males 9 
through 26 years at the time of the survey. HPV vaccination coverage might increase in the 
next several years since ACIP published a recommendation for routine use of HPV4 among 
males in December 20114.
Awareness of HPV and HPV affect vaccination coverage17. Assessing awareness of HPV 
and HPV vaccine is important for developing tailored intervention programs to improve 
HPV-related knowledge and vaccine uptake. In contrast to the findings from surveys of 
females one year after vaccine licensure that describe the awareness of both HPV and HPV 
vaccine as >80%17, our study found men had lower HPV and HPV vaccine awareness 
(51.8%, and 34.8%, respectively, 3-14 months after vaccine licensure; 50.0%, and 34.18%, 
respectively, about one year after vaccine licensure). One of the possible reasons may be that 
women are more concerned about cervical cancer and thus may have comparatively better 
knowledge on HPV and the HPV vaccine 18, 19. Another reason is that there was marketing 
about HPV disease (pre-vaccine licensure) and marketing about the vaccine (post-licensure) 
specifically directed at women20-32. In addition, routine vaccination for females was 
recommended by ACIP after vaccine licensure, however, ACIP only provided guidance that 
the HPV4 vaccine may be given to males 9 through 26 years and vaccination was not 
routinely recommended for males after vaccine licensure1, 12. This difference in 
recommendation may affect awareness of HPV and HPV vaccine between females and 
males. This difference in recommendation may confuse people and affect vaccine initiation 
for males. Other studies have similar findings and report that females had more HPV-related 
knowledge than males18, 19, 21.
Several characteristics were independently associated with higher awareness of HPV and the 
HPV vaccine. Racial and ethnic disparities were noted with non-Hispanic white men having 
significantly higher HPV and HPV vaccine awareness compared to Hispanic, non-Hispanic 
Asian, and non-Hispanic black men 18-26 years, though the disparity for non-Hispanic 
black men was no longer apparent after controlling for other factors. Higher education was 
also associated with higher HPV and HPV vaccine awareness among this age group, 
consistent with other studies17, 22. Education programs, materials, and information about 
HPV and the vaccine have been disseminated and provided to providers, patients/parent, and 
the general public 4, 23-27. Information about HPV and the vaccine may improve HPV and 
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HPV vaccine knowledge for diverse racial/ethnic groups and all educational levels28, 29. 
Educating men about HPV and HPV vaccination is particularly important because the HPV 
vaccine has been targeted toward women, mothers and adolescent girls with a focus on 
prevention of cervical cancer 23-27. With the addition of males in vaccine recommendations, 
newer materials need to address the issues and concerns of men.
Men with a greater number of physician contacts had higher awareness of HPV and HPV 
vaccine. Persons who have more frequent physician contact have more opportunities to 
discuss their health status and thus may know or understand more about vaccination. Studies 
showed that a doctor’s recommendation is a key determinant of HPV vaccine acceptability 
and uptake among females33, 34. Healthcare providers are one of the main sources of HPV 
vaccine information among females35, and may play an important role in vaccine uptake 
among males. Future interventions targeting healthcare providers might help increase HPV 
vaccine uptake among males. For example, physician vaccination reminder systems may 
help increase vaccination coverage but are underused by healthcare providers36, 37.
Lack of medical insurance has been associated with low adult vaccination17, 38-45. Our study 
indicated that approximately 36% males 18-26 years had no medical insurance. For 
uninsured individuals, there are limited opportunities to access a medical home or usual 
sources of care, which have been associated with lower vaccination coverage 46-48. 
Vaccination may need to be paid out of pocket for those without medical insurance and for 
some with medical insurance that does not cover the cost of the vaccine. The vaccine 
manufacturer has implemented a program (Merck Vaccine Patient Assistance Program), 
which provides free vaccines including the HPV vaccine to all adults who are uninsured and 
poor (household income less than $20,800 for individuals, $28,000 for couples, or $42,400 
for a family of four)49. The CDC’s Section 317 Grants Program provides the immunization 
infrastructure to deliver vaccines to underinsured children, and uninsured and underinsured 
adults50. This program might help improve vaccination coverage among uninsured and poor 
adult population, however, variation by state in how funds are used for HPV vaccination 
may affect vaccination coverage. Such resources are important for uninsured and 
underinsured individuals, but these funds are often insufficient for demand. Although these 
programs help provide for vaccines for adults, there is a recognized gap in coverage for adult 
immunizations 39-45, 51. The Affordable Care Act may help improve vaccination coverage 
since the expanded enrollment in public and private insurance programs expected from 
provisions of the Affordable Care Act is likely to improve access to health care services, 
including vaccination 52. Federal, state, and local partners should continue to build support 
for adult immunizations and address areas of need for uninsured populations.
The findings in this study are subject to limitations. Data for this study were collected by 
self report and vaccination was not verified by medical records. Previous studies have found 
that self-report of pneumococcal vaccination by adults was moderately or highly sensitive 
and moderately specific compared with reviews of medical records53, 54, and self-report of 
influenza vaccination by adults also has been shown to have high sensitivity and moderate 
specificity53. Validity studies regarding self-reported HPV vaccination compared with 
medical records among adults have not been reported, however, one study showed that 
parent-reported HPV vaccination was highly sensitive and specific compared with provider 
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report55. Additionally, few men reported HPV vaccine initiation, precluding further 
evaluation of predictors of HPV vaccine initiation.
In conclusion, soon after the vaccine was licensed, only 1.1% of men 18–26 years had 
initiated HPV vaccination and awareness of HPV and HPV vaccine among men were low. 
HPV vaccination coverage might increase in the next several years since ACIP published a 
recommendation for routine use of HPV4 among males in December 20114. Efforts should 
be directed to provide comprehensive, accessible, and appropriate communication messages 
on HPV and HPV vaccine directed to men. Greater use of strategies demonstrated to 
improve vaccination coverage are needed, including use of implementation of standing 
orders programs, use of media promotions and educational programs, and financing to 
reduce client out-of-pocket expenses 35, 56.
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TABLE 1
Characteristics of Men 18-26 years in the United States, by Demographic and Health Care Variables–The 2010 
National Health Interview Survey (NHIS 2010)
Characteristic Sample size (n) %
Total 1,741 100
Race/Ethnicity
 Non-Hispanic White 881 60.7
 Non-Hispanic Black 243 14.1
 Hispanic 469 19.5
No n-Hispanic Asian 101 3.4
 Other 47 2.3
Marital status
 Married 221 13.6
 Not married 1,517 86.4
Education
 Less than High School 274 15.8
 High School Graduate 531 32.1
 Some College 674 40.0
 ≥College Graduate 257 12.2
Employment status
 Currently Employed 1,133 64.1
 Not employed 607 35.9
Poverty level*
 300%+ 444 36.5
2 00% to <300% 242 16.3
 100% to <200% 388 23.5
 <100% 468 23.8
Immigration status
 Born in U.S. 1,406 86.3
Born outside U.S. and Stayed in the US ≤10 Years 196 7.1
Born outside U.S. and Stayed in the US >10 Years 139 6.6
Hospitalization within past year
 Yes 64 4.1
 No 1,677 95.9
Physician contacts within past year
 None 759 42.2
 1 383 21.3
 2–3 335 20.3
 4–9 190 12.9
 >10 55 3.3
Health insurance
 Private 902 54.2
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Characteristic Sample size (n) %
 Public 176 10.1
 None 650 35.7
Having a regular physician for health care
 Yes 1,038 64.3
 No 692 35.7
One/more recommended vaccines in life time†
 Yes 1,311 78.0
 No 410 22.0
Cigarette use
 Current Smoker 408 24.4
 Former Smoker 157 8.5
 Never Smoked 1,172 67.1
Month of interview
 January–May 691 39.0
 June–December 1,050 61.0
STD/HIV related high risk behavior‡
 Yes 140 6.6
 No 1,574 93.4
Household with a female adolescent
 Yes 132 10.5
 No 1,609 89.5
Ever heard of HPV
 Yes 830 51.8
 No 803 48.2
Ever heard of HPV vaccine
 Yes 546 34.8
 No 1,086 65.2
*
Poverty level is determined by the US Census Bureau based on household income and the number of persons living in the household.
†
Persons reported ever receiving hepatitis A (HepA), Hepatitis B (HepB), pneumococcal polysaccharide vaccine (PPV) or tetanus–diphtheria, 
tetanus–diphtheria–acellular pertussis (Td/Tdap) vaccines.
‡
Includes persons who considered themselves at high risk for HIV infection, persons who reported having a sexually transmitted disease other than 
HIV/AIDS during the previous 5 years, and persons who reported any one of the following risk factors: hemophilia with receipt of clotting factor 
concentrates, men who have sex with men, injecting street drugs, trading sex for money or drugs, testing positive for HIV, or having sex with 
someone with any of these risk factors.
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TABLE 2
Initiation of Human Papillomavirus (HPV) (≥1 dose) among Men 18–26 years in the United States, by 
Demographic and Health Care Variables–The 2010 National Health Interview Survey (NHIS 2010)
HPV vaccination coverage (≥1 dose)
Characteristic Sample size % 95% CI p-value
Total 1,741 1.1 (0.6, 2.2)
Race/Ethnicity
 Non-Hispanic White* 881 0.9 (0.3, 2.3)
Non-Hispanic Black 243 1.0 (0.3, 3.4) 0.921
 Hispanic 469 1.9 (0.5, 6.7) 0.488
Marital status
 Married* 221 0.9 (0.2, 3.7)
 Not married 1,517 1.2 (0.5, 2.5) 0.776
Education
 Less than High School* 274 2.4 (0.7, 8.1)
 High School Graduate 531 1.2 (0.3, 4.4) 0.446
 Some College 674 0.6 (0.3, 1.3) 0.207
 ≥College Graduate 257 1.1 (0.3, 3.7) 0.430
Employment status
 Currently Employed 1,133 1.0 (0.4, 2.4) 0.709
 Not employed* 607 1.3 (0.5, 3.7)
Poverty level†
 300%+ 444 0.8 (0.1, 5.3) 0.197
 200% to <300% 242 0.7 (0.2, 2.9) 0.110
 100% to <200% 388 0.4 (0.1, 1.7) 0.025‡
 <100%* 468 2.1 (1.1, 4.1)
Health insurance
 Private 902 1.4 (0.6, 3.5) 0.210
 Public 176 1.8 (0.7, 4.5) 0.181
 None* 650 0.6 (0.2, 1.6)
Having a regular physician for health care
 Yes 1,038 1.5 (0.7, 3.2) 0.125
 No* 692 0.5 (0.2, 1.5)
Month of interview
 January-May* 691 1.1 (0.5, 2.1)
 June-December 1,050 1.1 (0.4, 3.2) 0.922
STD/HIV related high risk behavior§
 Yes 140 1.4 (0.3, 6.0) 0.809
 No* 1,574 1.1 (0.5, 2.3)
Household with a female adolescent
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HPV vaccination coverage (≥1 dose)
Characteristic Sample size % 95% CI p-value
 Yes 132 0.0 ‖ N/A
 No* 1,609 1.2 (0.6, 2.5)
Ever heard of HPV
 Yes 830 2.0 (1.0, 4.2) 0.018‡
 No* 803 0.2 (0.0, 0.9)
Ever heard of HPV vaccine
 Yes 546 2.8 (1.3, 5.9) 0.020‡
 No* 1,086 0.2 (0.1, 0.8)
*
Reference level.
†
Poverty level is determined by the US Census Bureau based on household income and the number of persons living in the household.
‡p<0.05 by T test for comparisons within each variable with the indicated reference level.
§
Includes persons who considered themselves at high risk for HIV infection, persons who reported having a sexually transmitted disease other than 
factors: hemophilia with receipt of clotting factor concentrates, men who have sex with men, injecting street drugs, trading sex for money or drugs, 
testing positive for HIV, or having sex with someone with any of these risk factors.
‖No respondents receiving vaccination in this group.
N/A: Not applicable.
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TABLE 3
Awareness of Human Papillomavirus and Human Papillomavirus vaccine among Men 18-26 years, by 
Demographic and Health Care Variables –The 2010 National Health Interview Survey (NHIS 2010)
Percentage of 
Awareness of 
Human 
Papillomavirus Prevalence Ratio (adjusted)
Percentage of 
Awareness of 
Human 
Papillomavirus 
vaccine Prevalence Ratio (adjusted)
Characteristic % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Total 51.8 (48.7, 54.8) 34.8 (31.7, 38.0)
Race/Ethnicity
 Non-Hispanic White* 60.0 (55.8, 64.1) Referent 40.0 (35.7, 44.4) Referent
 Non-Hispanic Black
  46.1 (37.9, 54.4)† 1.0 (0.8–1.2) 33.1 (26.1, 40.9) 1.0 (0.8–1.3)
 Hispanic
  31.6 (26.8, 36.9)†   0.7 (0.6–0.9)†   21.4 (16.7, 27.0)†   0.7 (0.6–1.0)†
 Non-Hispanic Asian
  31.9 (19.8, 47.2)†   0.6 (0.4–0.9)†   24.5 (15.0, 37.5)† 0.8 (0.5–1.3)
 Other 70.2 (48.0, 85.7) 1.4 (1.1–1.7) 37.4 (21.8, 56.1) 1.1 (0.7–1.7)
Marital status
 Married* 45.9 (38.1, 53.9) Referent 28.4 (22.0, 36.0) Referent
 Not married 52.7 (49.4, 56.1) 1.1 (0.9–1.3) 35.8 (32.5, 39.3) 1.1 (0.9–1.4)
Education
 Less than High School* 32.4 (25.6, 40.1) Referent 22.4 (16.7, 29.4) Referent
 High School Graduate
  45.6 (40.1, 51.2)† 1.3 (1.0–1.6) 26.0 (21.1, 31.4) 1.0 (0.7–1.4)
 Some College
  60.9 (55.9, 65.6)†   1.6 (1.2–2.0)†   43.0 (37.9, 48.3)†   1.4 (1.0–1.9)†
 ≥College Graduate
  65.0 (57.4, 71.9)†   1.6 (1.3–2.1)†   48.8 (39.8, 57.8)†   1.6 (1.1–2.2)†
Employment status
 Currently Employed* 52.4 (48.5, 56.4) Referent 37.1 (33.3, 41.2) Referent
 Not employed 50.7 (45.8, 55.5) 1.0 (0.9–1.2)
  30.7 (26.2, 35.6)† 0.8 (0.7–1.0)
Poverty level§
 300%+
  59.4 (53.5, 65.2)† 1.1 (0.9–1.3)   42.9 (36.7, 49.3)† 1.2 (0.9–1.5)
 200% to <300% 51.1 (43.3, 58.8) 1.1 (0.9–1.3)
  38.2 (31.1, 46.0)† 1.2 (1.0–1.6)
 100% to <200% 45.7 (39.5, 52.0) 1.1 (0.9–1.2) 30.1 (25.1, 35.6) 1.0 (0.8–1.3)
 <100%‡ 43.6 (37.6, 49.9) Referent 27.4 (22.7, 32.7) Referent
Immigration status
 Born in U.S.* 55.0 (51.5, 58.5) Referent 37.4 (34.0, 41.0) Referent
 Born outside U.S. and 
stayed in the US ≤10 years
  19.0 (13.7, 25.7)†   0.6 (0.5–0.9)†   9.6 (5.7, 15.7)†   0.5 (0.3–0.8)†
 Born outside U.S. and 
stayed in the US >10 years
44.6 (34.2, 55.4) 1.1 (0.9–1.4) 27.3 (18.0, 39.2) 0.9 (0.6–1.3)
Hospitalization within past year
 Yes 61.4 (45.3, 75.4) 0.9 (0.6–1.2) 36.8 (22.9, 53.4) 1.0 (0.6–1.5)
 No* 51.4 (48.2, 54.5) Referent 34.7 (31.5, 38.0) Referent
Am J Prev Med. Author manuscript; available in PMC 2018 February 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Lu et al. Page 16
Percentage of 
Awareness of 
Human 
Papillomavirus Prevalence Ratio (adjusted)
Percentage of 
Awareness of 
Human 
Papillomavirus 
vaccine Prevalence Ratio (adjusted)
Characteristic % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Physician contacts within past year
 None* 43.2 (38.6, 47.9) Referent 27.4 (23.5, 31.8) Referent
 1 51.7 (44.4, 58.9) 1.1 (0.9–1.3) 32.5 (26.3, 39.3) 1.1 (0.9–1.4)
 2–3
  59.0 (52.2, 65.4)†   1.2 (1.0–1.4)†   46.0 (39.4, 52.7)†   1.4 (1.2–1.8)†
 4–9
  66.4 (58.3, 73.6)†   1.3 (1.1–1.6)†   46.9 (37.8, 56.1)†   1.3 (1.0–1.7)†
 >10
  66.1 (48.8, 80.0)† 1.4 (1.0–1.8) 31.8 (18.6, 48.7) 1.1 (0.7–1.8)
Health insurance
 Private
  61.4 (57.1, 65.6)†   1.3 (1.1–1.6)†   43.4 (38.8, 48.2)†   1.4 (1.1–1.7)†
 Public 40.4 (32.1, 49.3) 1.0 (0.8–1.3) 24.0 (17.4, 32.1) 1.1 (0.8–1.5)
 None* 40.7 (35.9, 45.7) Referent 24.6 (20.5, 29.3) Referent
Having a regular physician 
for health care
 Yes* 53.8 (49.8, 57.8) Referent 36.4 (32.5, 40.4) Referent
 No 48.3 (43.4, 53.1)
  0.9 (0.8–1.0)† 32.1 (27.8, 36.7)   0.8 (0.7–1.0)†
One/more recommended 
vaccines in life time§
 Yes
  56.0 (52.6, 59.5)†   1.3 (1.1–1.5)†   37.4 (34.0, 41.0)†   1.3 (1.0–1.6)†
 No* 36.5 (30.5, 43.0) Referent 25.2 (19.4, 32.0) Referent
Cigarette use
 Current Smoker* 52.6 (46.7, 58.5) Referent 33.1 (27.1, 39.6) Referent
 Former Smoker 61.0 (51.8, 69.4) 1.0 (0.8–1.2) 32.3 (23.8, 42.1) 0.8 (0.6–1.2)
 Never Smoked 50.3 (46.3, 54.3) 0.9 (0.8–1.0) 35.8 (32.0, 39.7) 1.0 (0.8–1.3)
Month of interview
 January–May* 54.4 (50.0, 59.3) Referent 35.2 (30.3, 40.3) Referent
 June–December 50.0 (45.8, 54.3) 0.9 (0.8–1.0) 34.1 (30.1, 38.4) 1.0 (0.8–1.2)
STD/HIV related high risk 
behavior‖
 Yes
  62.5 (52.9, 71.3)†   1.3 (1.1–1.5)†   45.6 (36.0, 55.4)‡   1.3 (1.0–1.7)†
 No* 51.0 (47.8, 54.2) Referent 34.0 (30.8, 37.4) Referent
Household with a female 
adolescent
 Yes 45.4 (34.8, 56.3) 1.0 (0.8–1.3) 34.3 (24.7, 45.3) 1.2 (0.9–1.6)
 No* 52.5 (49.3, 55.7) Referent 34.5 (31.3, 37.9) Referent
*
Reference level for comparison of percentage of awareness of Human Papillomavirus and Human Papillomavirus vaccine from bivariable 
analysis.
†p<0.05 by T test for comparisons within each variable with the indicated reference level.
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‡
Poverty level is determined by the US Census Bureau based on household income and the number of persons living in the household.
§
Persons reported ever receiving hepatitis A (HepA), Hepatitis B (HepB), pneumococcal polysaccharide vaccine (PPV) or tetanus–diphtheria, 
tetanus–diphtheria–acellular pertussis (Td/Tdap) vaccines.
‖
Includes persons who considered themselves at high risk for HIV infection, persons who reported having a sexually transmitted disease other than 
HIV/AIDS during the previous 5 years, and persons who reported any one of the following risk factors: hemophilia with receipt of clotting factor 
concentrates, men who have sex with men, injecting street drugs, trading sex for money or drugs, testing positive for HIV, or having sex with 
someone with any of these risk factors.
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